Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second -line chemotherapy for the Koreans (Asian population) with gemcitabineresistant or -refractory advanced pancreatic cancer.

被引：0
|
作者：
Lee, Sang-Cheol
Kim, Jung Hoon
Oh, Sung Yong
Kim, Kyoungha
Song, Seo-Young
Lee, Namsu
Nam, Eun M. I.
Lee, Soonil
Hwang, In Gyu
Lee, Hyo Rak
Won, jong-Ho
Lee, Kyu Taek
Bae, Sang-Byung
Kim, Hanjo
Kim, Hyun Jung
Jang, JoungSoon
Lim, Do Hyoung
Lee, Hyun Woo
Kang, Jung Hun
机构：
[1] Soonchunhyang Univ Hosp Seoul, Coll Med, Dept Internal Med,Div Hematol Oncol, Seoul, South Korea
[2] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[3] Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea
[4] Soonchunhyang Univ Hosp Seoul, Seoul, South Korea
[5] Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med, Chunchon, South Korea
[6] Ewha Womans Univ, Seoul, South Korea
[7] Dankook Univ Hosp, Coll Med, Dept Internal Med, Cheonan, South Korea
[8] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[9] Korea Canc Ctr Hosp, Dept Internal Med, Seoul, South Korea
[10] Soonchunhyang Univ, Cheonan Hosp, Cheonan, South Korea
[11] Soonchunhyang Univ Hosp Cheonan, Cheonan, South Korea
[12] Soonchunhayng Univ, Coll Med, Bucheon Hosp, Bucheon, South Korea
[13] Chung Ang Univ Hosp, Seoul, South Korea
[14] Dankook Univ Hosp, Cheonan, South Korea
[15] Ajou Univ Hosp, Suwon, South Korea
[16] Gyeongsang Natl Univ Hosp, Sch Med, Div Hematol Oncol, Dept Internal Med, Jinju, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15731
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Assaf, Elias
    Verlinde-Carvalho, Muriel
    Delbaldo, Catherine
    Grenier, Julien
    Sellam, Zineb
    Pouessel, Damien
    Bouaita, Linda
    Baumgaertner, Isabelle
    Sobhani, Iradj
    Tayar, Claude
    Paul, Muriel
    Culine, Stephane
    ONCOLOGY, 2011, 80 (5-6) : 301 - 306
  • [22] Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma -: Results of a phase II trial
    Mitry, E
    Ducreux, M
    Ould-Kaci, M
    Boige, V
    Seitz, JF
    Bugat, R
    Breau, JL
    Bouché, O
    Etienne, PL
    Tigaud, JM
    Morvan, F
    Cvitkovic, E
    Rougier, P
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2006, 30 (03): : 357 - 363
  • [23] Oxaliplatin, 5-FU and folinic acid (OFFA) as II-line chemotherapy in advanced colorectal cancer
    Tassinari, D
    Panzini, I
    Pasquini, E
    Desiderio, F
    Drudi, G
    Fattori, PP
    Gianni, L
    Oliveno, G
    Tononi, A
    Ravaioli, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S80 - S80
  • [24] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy.
    Ng, M
    Norman, AR
    Cunningham, D
    Waters, J
    Oates, J
    Ross, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 370S - 370S
  • [26] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
    Lee, Min Geun
    Lee, Sang Hyub
    Lee, Seung June
    Lee, Yoon Suk
    Hwang, Jin-Hyeok
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kim, Dong Uk
    Woo, Sang Myung
    CHEMOTHERAPY, 2013, 59 (04) : 273 - 279
  • [27] COST-EFFECTIVENESS ANALYSIS OF PHARMACOKINETIC-GUIDED (PK) 5-FLUOROURACIL (5-FU) DOSING WHEN COMBINED WITH LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) CHEMOTHERAPY FOR ADVANCED PANCREAS CANCER
    Egues, A.
    Aldaz, A.
    Rodriguez, J.
    Delgado, L.
    Ortega, A.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [28] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
    Ioka, T.
    Nakamori, S.
    Sugimori, K.
    Kanai, M.
    Ikeda, M.
    Ozaka, M.
    Furukawa, M.
    Okusaka, T.
    Kawabe, K.
    Furuse, J.
    Komatsu, Y.
    Sato, A.
    Shimizu, S.
    Chugh, P.
    Tang, R.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Phase II study of irinotecan and high dose infusional 5-fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer.
    Leonard, P
    Ledermann, J
    James, R
    Hochhauser, D
    Seymour, M
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 45
  • [30] Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU
    Tsutsumi, S
    Yamaguchi, S
    Ide, M
    Tsuboi, K
    Fukasawa, T
    Yamaki, S
    Asao, T
    Kuwano, H
    HEPATO-GASTROENTEROLOGY, 2006, 53 (68) : 196 - 200
12345